
Eli Lilly Bets $3.8B on Psychedelic Medicine with AtaiBeckley Deal
Eli Lilly's up-to-$3.8 billion acquisition of clinical-stage AtaiBeckley marks the largest psychedelic medicine investment to date, targeting a fast-growing treatment-resistant depression market…




























